CELLTRION
LIVE

Serial Number

79101488

Owner

CELLTRION, INC.

Attorney

Kisuk Lee

Filing Date

Apr 1, 2011

Add to watchlist:

No watchlists yet
View on USPTO

CELLTRION Trademark

Serial Number: 79101488 • Registration: 4169803

CELLTRION is a trademark filed by CELLTRION, INC. on April 1, 2011. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

CELLTRION, INC. (115 trademarks)

23, Academy-ro,

Entity Type: 03

Celltrion Holdings Co.,Ltd. (15 trademarks)

5th, 19, Academy-ro 51beon-gil,
Incheon 22014 , KR

Entity Type: 03

Trademark Details

Filing Date

April 1, 2011

Registration Date

July 10, 2012

Published for Opposition

April 24, 2012

Goods & Services

[ Rental of medical and health care equipment; medical product information, namely, providing an interactive holistic web site featuring health information and patient initiated, patient authorized, fee-for-service, holistic approach distance healing sessions based on the patient's specific set of symptoms, medical profile and medical record analysis and patient benefit information concerning organic and holistic products and services; medical clinics, namely, conducting clinical trials of new products for medical purposes; hospitals; medical assistance services; biopharmaceutical consulting service ]

Treatment of biopharmaceutical materials, namely, processing finished products from raw biopharmaceutical materials; treatment service of biopharmaceutical materials for others, namely, processing finished products from raw biopharmaceutical materials for others; contract manufacturing service for others in the field of biopharmaceuticals; contract manufacturing service in the field of pharmaceuticals

[ Vaccines; medicines for sensory organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of sensory organ; agents affecting peripheral nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the peripheral nervous system; agents for immunity adjustment, namely, pharmaceutical preparations for the prevention and treatment of disorders of the immune system; biological preparations for medical purposes; amino acids for medical purposes; antibiotic preparations; agents for respiratory organs, namely, pharmaceutical preparations for the prevention and treatment of disorders of respiratory organs; chemotherapeutics; reagents for measuring Hepatitis B Surface antibody, namely, medical diagnostic reagents for detecting Hepatitis B surface antibody; diagnostic preparations for medical use; AIDS, acquired immune deficiency syndrome diagnostic agents, namely, diagnostic preparation for medical use; AIDS, acquired immune deficiency syndrome vaccines; agents affecting central nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the nervous system; veterinary vaccines; agents for tumor treatment, namely, pharmaceutical preparations for the treatment of tumor; agents for urogenital organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of urogenital organs; kits for protein test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a protein related to a disease; kits for gene test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a gene related to a disease; biopharmaceuticals for the treatment and prevention of infectious diseases, tumor-related diseases, auto-immune diseases, hormone-deficiency diseases; biopharmaceutical preparations, namely, polypeptides, proteins, monoclonal antibodies, hormones for the treatment and prevention of infectious diseases, tumor-related diseases, auto-immune diseases, hormone deficiency diseases; biotherapeutic preparations and substances for medical purposes; biotechnological preparations for medical purposes; pharmaceuticals; chemical preparations for pharmaceutical purposes, namely, chemical reagents for medical purposes; chemico-pharmaceutical preparations ]

Wholesale distributorships featuring pharmaceutical products; retail store services featuring pharmaceutical products; business intermediary services in the field of pharmaceutical products; wholesale distributorships featuring biopharmaceutical products; retail store services featuring biopharmaceutical products; business intermediary services in the field of biopharmaceutical products

Pharmaceutical research and development; [ bacteriological research; biological research; research and development for new products for others; material testing; chemistry services, namely, chemistry consultation; chemical research and analysis; technology outsourcing services on biopharmaceuticals manufacturing, namely, conducting biopharmaceutical research services for others; consulting services in the field of biotechnology; pharmaceutical drug development services with animal cell; scientific research related to genetically modified plant; biotechnology research; ] biopharmaceutical research and development [; medical product testing; technology outsourcing services on selecting medicines, namely, conducting pharmaceutical research services for others ]

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Oct 21, 2023 ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 2, 2022 ADCH
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Aug 17, 2022 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Aug 17, 2022 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 16, 2022 APRE
TEAS SECTION 71 & 15 RECEIVED
Mar 18, 2022 ES75
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 5, 2021 CORN
CHANGE OF NAME/ADDRESS REC'D FROM IB
Sep 18, 2021 ADCH
CORRECTION TRANSACTION RECEIVED FROM IB
Sep 10, 2021 CRCV
CHANGE OF OWNER RECEIVED FROM IB
Aug 6, 2021 CHLD
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jul 10, 2021 REM4
INTERNATIONAL REGISTRATION RENEWED
Jul 2, 2021 RNWL
NEW REPRESENTATIVE AT IB RECEIVED
Apr 30, 2021 NREP
PARTIAL INVALIDATION PROCESSED BY THE IB
Apr 19, 2019 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Mar 23, 2019 INPS
INVALIDATION PROCESSED
Mar 23, 2019 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Mar 20, 2019 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Jul 20, 2018 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Jul 20, 2018 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 18, 2018 APRE
TEAS SECTION 71 RECEIVED
Jun 21, 2018 ES71
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 21, 2018 EWAF
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 10, 2017 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 26, 2015 ADCH
CORRECTION UNDER SECTION 7 - PROCESSED
Oct 11, 2013 COC.
ASSIGNED TO PARALEGAL
Oct 11, 2013 PLGL
LIMITATION FROM THE IB EXAMINED AND ENTERED
Oct 11, 2013 LIME
LIMITATION OF GOODS RECEIVED FROM IB
Aug 30, 2013 LIMG
NOTIFICATION PROCESSED BY IB
Dec 2, 2012 GPNX
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 4, 2012 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 16, 2012 FICS
FINAL DISPOSITION PROCESSED
Oct 16, 2012 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 10, 2012 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 10, 2012 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 24, 2012 NPUB
PUBLISHED FOR OPPOSITION
Apr 24, 2012 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 4, 2012 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 4, 2012 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 4, 2012 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 19, 2012 PREV
ASSIGNED TO LIE
Mar 19, 2012 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 2, 2012 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 2, 2012 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 2, 2012 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 2, 2012 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 2, 2012 CNEA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 15, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 15, 2011 REAP
REFUSAL PROCESSED BY IB
Oct 18, 2011 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 23, 2011 RFCS
REFUSAL PROCESSED BY MPU
Sep 22, 2011 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 22, 2011 RFCR
NON-FINAL ACTION WRITTEN
Sep 21, 2011 CNRT
APPLICATION FILING RECEIPT MAILED
Sep 13, 2011 MAFR
ASSIGNED TO EXAMINER
Sep 9, 2011 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 9, 2011 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 8, 2011 REPR